Bristol's HCV Bump Catalyzes Strong Quarter, But Not Expected To Last
Executive Summary
Daklinza has been part of the standard of care in genotype 3 HCV, but the launch of Gilead's Epclusa and an EU ramp-up of Merck's Zepatier are expected to erode that over time.
You may also be interested in...
Bristol Stresses Cost Control Despite Strong Earnings Quarter
Pharma pledges level operating expenses from 2016 to 2020, despite a planned uptick in 2017 R&D spend. Sales were strong almost across the board for Bristol during the third quarter, but headwinds are coming, especially in immuno-oncology.
Will Real-World Data Sway Course Of Novel Anticoagulant Market?
A wave of data to support use of novel anticoagulants in real-world settings was presented at the European Society of Cardiology Congress, but the question is whether this will alter the course of the market still dominated by warfarin and trailed by J&J/Bayer's Xarelto.
Gilead Sees Prospects For Declining HCV Revenues To Stabilize
A confluence of factors, including a higher proportion of patients covered by public payers, has caused Gilead's powerhouse hepatitis C franchise to slow down and now begin showing signs of decline.